FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a …
Read More